Cargando…
A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy
Immune checkpoint blockade (ICB) therapies that target programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway are currently used for the treatment of various cancer types. However, low response rates of ICB remain the major issue and limit their applications in clinic. Here, w...
Autores principales: | Hu, Doudou, Zhang, Wei, Xiang, Jiajia, Li, Dongdong, Chen, Yong, Yuan, Pengcheng, Shao, Shiqun, Zhou, Zhuxian, Shen, Youqing, Tang, Jianbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130108/ https://www.ncbi.nlm.nih.gov/pubmed/35647515 http://dx.doi.org/10.1016/j.mtbio.2022.100284 |
Ejemplares similares
-
Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy
por: Xiang, Jiajia, et al.
Publicado: (2023) -
Multipotent Poly(Tertiary Amine‐Oxide) Micelles for Efficient Cancer Drug Delivery
por: Xiang, Jiajia, et al.
Publicado: (2022) -
“One-for-All” approach: a black technology for nanomedicine development?
por: Xiang, Jiajia, et al.
Publicado: (2023) -
Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
por: Xiang, Dongquan, et al.
Publicado: (2023) -
Extracellular vesicles hybrid plasmid-loaded lipid nanovesicles for synergistic cancer immunotherapy
por: Tong, Qing, et al.
Publicado: (2023)